Avalon Pharmaceuticals, Inc. (NASDAQ: AVRX), a biopharmaceutical company, is committed to discovering, developing and commercializing superior cancer therapeutics. The company’s proprietary platform, AvalonRx®, is designed to discover and develop therapeutics for pathways that have been characterized as “undruggable” in the past. For further information, visit the Company’s web site at www.avalonrx.com.
- 17 years ago
QualityStocks
Avalon Pharmaceuticals, Inc. (NASDAQ: AVRX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Q2 2025 Results Show Record First-Half Profitability, Strong U.S. Contract Wins
SuperCom (NASDAQ: SPCB), a global provider of secured e-Government, IoT, and cybersecurity solutions, reported Q2…
-
QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Webull Financial Biotech/MedTech Webinar Series
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company developing novel treatments for primary and metastatic cancers…
-
QualityStocksNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) Showcases Emergency Command Platform at Indonesia Disaster Expo
FingerMotion (NASDAQ: FNGR) announced that its subsidiary, Shanghai JiuGe Information Technology Co., Ltd., is presenting…